Anti-endotrophin monoclonal antibody

Anti-endotrophin monoclonal antibody has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Nov 9, 2026: “Blood hormone adds to heart failure risk prediction in obesity”.

Intervention

1 paper studies itUpdated

1 new paper in 30 daysSee all 1 papers on anti-endotrophin monoclonal antibody

  • Humans1

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
AHA Scientific Sessions 2026 Abstract

Blood hormone adds to heart failure risk prediction in obesity

Over 13 years, heart failure developed in 9.69% of adults with obesity in the highest endotrophin group versus 3.12% in the lowest.Over 13 years, heart failure developed in 9.69% of adults with obesity in the highest endotrophin group versus 3.12% in the lowest.

Cohort · 7,728 peopleHeart failure